Los Angeles Capital Management LLC Lowers Stake in SIGA Technologies, Inc. (NASDAQ:SIGA)

Los Angeles Capital Management LLC cut its position in shares of SIGA Technologies, Inc. (NASDAQ:SIGA) by 16.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 87,843 shares of the company’s stock after selling 17,300 shares during the quarter. Los Angeles Capital Management LLC owned about 0.12% of SIGA Technologies worth $528,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of SIGA. Larson Financial Group LLC purchased a new stake in shares of SIGA Technologies during the 3rd quarter worth about $30,000. EP Wealth Advisors LLC purchased a new stake in SIGA Technologies during the third quarter worth approximately $82,000. XTX Topco Ltd purchased a new stake in SIGA Technologies during the third quarter worth approximately $85,000. Intech Investment Management LLC acquired a new stake in shares of SIGA Technologies in the third quarter worth $120,000. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in shares of SIGA Technologies by 30.0% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 19,902 shares of the company’s stock valued at $120,000 after acquiring an additional 4,597 shares during the period. 55.40% of the stock is currently owned by hedge funds and other institutional investors.

SIGA Technologies Trading Down 1.8 %

NASDAQ:SIGA opened at $5.39 on Tuesday. The firm’s fifty day simple moving average is $6.05 and its 200 day simple moving average is $6.87. SIGA Technologies, Inc. has a twelve month low of $4.75 and a twelve month high of $12.83. The firm has a market capitalization of $384.87 million, a price-to-earnings ratio of 4.49 and a beta of 0.94.

About SIGA Technologies

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.